Can Terbinafine Cause Vasculitis?
Yes, terbinafine can cause vasculitis, though this is a rare adverse event reported in postmarketing surveillance.
Evidence from FDA Drug Label
The FDA-approved drug label for terbinafine explicitly lists vasculitis among the adverse reactions identified during postmarketing experience 1. While the exact frequency cannot be reliably estimated due to voluntary reporting from an uncertain population size, vasculitis is recognized as a documented adverse effect of terbinafine therapy.
Clinical Context and Severity
The postmarketing data reveals that terbinafine-associated vasculitis can present as:
- Cutaneous vasculitis (most common presentation)
- Systemic vasculitis with potential multi-organ involvement
- Leukocytoclastic vasculitis (confirmed by skin biopsy) 2
A 2024 case report documented a fatal case of drug-induced vasculitis following terbinafine and/or itraconazole use, where the patient developed multi-organ failure and cutaneous vasculitis 2. The patient's autoimmune and infectious workup was negative, and skin biopsy confirmed leukocytoclastic vasculitis, strongly suggesting drug causation.
Risk Assessment and Clinical Implications
The overall risk is very low. According to the British Association of Dermatologists guidelines, terbinafine has an excellent safety profile with serious adverse events occurring in only 0.04% of patients 3. The most common side effects are gastrointestinal (49%) and dermatological (23%), such as rash, pruritus, and urticaria 3.
However, when vasculitis does occur:
- It may present with skin rash, fever, and multi-organ dysfunction 2
- Early recognition is critical, as delayed diagnosis can be fatal 2
- The condition is frequently overlooked in community practice 2
Management Algorithm
If vasculitis is suspected during terbinafine therapy:
- Immediately discontinue terbinafine - withdrawal of the offending agent is often sufficient to induce prompt resolution 4
- Exclude other causes - rule out autoimmune diseases and bacterial infections through appropriate testing
- Consider skin biopsy if diagnosis is uncertain
- Monitor for multi-organ involvement - check renal function, liver enzymes, and other organ systems
- Initiate supportive care - most cases resolve with drug withdrawal alone; severe cases may require corticosteroids or immunosuppressive therapy 2
Important Caveats
- Drug-induced vasculitis (DIV) is actually the most common form of vasculitis overall 4, though terbinafine-specific cases remain rare
- Over-the-counter availability of terbinafine may lead to underreporting of this adverse effect 2
- The differential diagnosis between drug-induced and idiopathic vasculitis can be challenging; drug withdrawal helps distinguish between these conditions 4
- Patients should be counseled about this rare but serious risk, particularly if they develop new rash, fever, or systemic symptoms during treatment
Bottom Line for Prescribers
While terbinafine remains the first-line treatment for dermatophyte onychomycosis based on superior efficacy and tolerability 3, maintain clinical vigilance for vasculitis. Any patient presenting with unexplained rash, fever, or multi-organ dysfunction while on terbinafine should prompt immediate consideration of drug-induced vasculitis, discontinuation of the medication, and appropriate workup.